62-67-9

Basic information

• Product Name: NALORPHINE
• Synonyms: 7,8-didehydro-4,5-epoxy-17-(2-propenyl)morphinan-3,6-diol;Acetorfin;Acetorphine;Allorphine;Anarcon;Anthorphine;Antofin;Antorfin
• CAS NO: 62-67-9
• Molecular Formula: C₁₉H₂₁NO₃
• Molecular Weight: 311.37
• EINECS: 200-546-1
• Mol File: 62-67-9.mol
• Article Data: 1

Chemical Properties

• Melting Point: 208-209° (not 92-93° as first given by McCawley)
• Boiling Point: 451.42°C (rough estimate)
• Flash Point: 252.3°C
• Appearance: /
• Density: 1.1699 (rough estimate)
• Vapor Pressure: 1.46E-10mmHg at 25°C
• Refractive Index: 1.5000 (estimate)
• PKA: pKa 7.73(H2O,t =20,I<0.01) (Uncertain)
• CAS DataBase Reference: NALORPHINE(CAS DataBase Reference)
• NIST Chemistry Reference: NALORPHINE(62-67-9)
• EPA Substance Registry System: NALORPHINE(62-67-9)

Safety Data

• Hazardous Substances Data: 62-67-9(Hazardous Substances Data)

Usage

Description

NALORPHINE, a synthetic opioid antagonist, is a derivative of morphine with potent antagonistic properties at opioid receptors. It is structurally related to naloxone and naltrexone, sharing their ability to reverse the effects of opioids. NALORPHINE exhibits mixed agonist-antagonist activity, meaning it can both stimulate and block opioid receptors, depending on the context and dosage. This unique characteristic makes it a versatile compound in medical and research applications.

Uses

Used in Medical Applications:
NALORPHINE is used as an antidote for acute morphine poisoning, helping to rapidly reverse the life-threatening respiratory depression caused by opioid overdose. Its mixed agonist-antagonist properties allow it to displace opioids from their receptors, restoring normal respiratory function and counteracting the sedative effects.
Used in Research:
NALORPHINE serves as a valuable biochemical research tool for studying the mechanism of narcotic action. Its ability to interact with opioid receptors in various ways provides insights into the complex processes underlying opioid addiction, tolerance, and dependence. This knowledge is crucial for developing new therapeutic strategies to combat opioid abuse and improve patient care.

InChI:InChI=1/C19H21NO3/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20/h2-6,12-13,15,18,21-22H,1,7-10H2/t12-,13+,15-,18-,19-/m0/s1

Upstream product

• 58229-59-7 17-allyl-4,5α-epoxy-3,6α-bis-vinyloxycarbonyloxy-morphin-7-ene 
• 57934-01-7 4,5α-epoxy-3,6α-bis-vinyloxycarbonyloxy-morphin-7-ene; hydrobromide 
• 106-95-6 allyl bromide 
• 466-97-7 normorphine 

Downstream Products

• 1477-58-3 (-)-N-allyl-norapomorphine*HCl 
• 1403776-93-1 7,8-didehydro-4,5-epoxy-17-(2-propenyl)-(5α,6α)-morphinan-3,6-diol 3,6-dibenzoate 
• 29622-51-3 Nalorphin-6-yl-ss-D-glucopyranosiduronsaeure 
• 24459-59-4 Nalorphin-3-yl-ss-D-glucopyranosiduronsaeure 
• 73853-11-9 3-O-acetylnalorphine 
• 14419-91-1 Morphin-N-allyl-iodid, N-Allyl-morphinium-iodid 

Relevant articles and documents

Combination of selected opioids with muscarine antagonists for treating urinary incontinence

Active compound combinations of compounds of group A, particularly opioids, and compounds of group B, particularly anti-muscarine agents and other substances suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.